Bill Text: MI HB4607 | 2019-2020 | 100th Legislature | Introduced

---

Bill Title: Health; testing; disclosure of Lyme disease information; require of health care providers, and require certain tests to be ordered. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 16279.

Spectrum: Moderate Partisan Bill (Democrat 15-3)

Status: (Introduced - Dead) 2019-05-21 - Bill Electronically Reproduced 05/21/2019 [HB4607 Detail]

Download: Michigan-2019-HB4607-Introduced.html

---

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HOUSE BILL No. 4607

 

 

May 16, 2019, Introduced by Reps. Whitsett, Peterson, Elder, Yancey, Rendon, Hoitenga, Garza, Tate, Chirkun, Cambensy, Haadsma, Kennedy, Brenda Carter, Wozniak, Neeley, Coleman, Jones and Robinson and referred to the Committee on Health Policy.

 

     A bill to amend 1978 PA 368, entitled

 

"Public health code,"

 

(MCL 333.1101 to 333.25211) by adding section 16279.

 

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

 

     Sec. 16279. (1) A licensee who orders a laboratory test for

 

the presence of Lyme disease in a human patient shall order an

 

enzyme-linked immunosorbent assay test and a western blot assay

 

test and shall provide the patient or his or her legal

 

representative with written materials on Lyme disease and testing

 

for Lyme disease before the tests are performed. The written

 

materials must include, but are not limited to, all of the

 

following:

 

     (a) Information on each of the following:

     (i) Available treatment options for Lyme disease.

 

     (ii) A list of physicians with expertise in treating Lyme

 

disease.

 

     (iii) The symptoms and complications that an individual who is

 

diagnosed with Lyme disease may experience.

 

     (b) A notice in substantially the following form:

 

     "Your health care provider has ordered a laboratory test for

 

the presence of Lyme disease for you. Current laboratory testing

 

for Lyme disease can be problematic and standard laboratory tests

 

often result in false negative and false positive results. If

 

tested too early, you may not have produced enough antibodies to be

 

considered positive because your immune response requires time to

 

develop antibodies. If you are tested for Lyme disease and the

 

results are negative, this does not necessarily mean that you do

 

not have Lyme disease. If you continue to experience unexplained

 

symptoms, you should contact your health care provider and inquire

 

about the appropriateness of retesting or initial or additional

 

treatment.".

 

     (2) A licensee who prescribes, administers, or dispenses any

 

of the following for the treatment of Lyme disease in a human

 

patient is not subject to administrative action under sections

 

16221 and 16226:

 

     (a) An oral long-term antibiotic.

 

     (b) An intravenous antibiotic administered through a vascular

 

access device.

 

     Enacting section 1. This amendatory act takes effect 90 days

 

after the date it is enacted into law.